Related Experiment Video
Updated: Aug 13, 2026
Development and Validation of a Quantitative PCR Method for Equid Herpesvirus-2 Diagnostics in Respiratory Fluids
Published on: March 17, 2016
Potency estimation of measles, mumps and rubella trivalent vaccines with quantitative PCR infectivity assay
J A C Schalk1, C G J C A de Vries, P M J M Jongen
1National Institute for Public Health and the Environment, Centre for Biological Medicines and Medical Technology, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands. marjolijn.schalk@rivm.nl
Abstract:
The quantitative PCR infectivity assay is a combination of virus propagation and quantitative PCR. Previously [Schalk JAC, van den Elzen C, Ovelgonne H, Baas C, Jongen PMJM. Estimation of the number of infectious measles viruses in live virus vaccines using quantitative real-time PCR. J Virol Methods 2004;117:179-87.], we used this assay to estimate the titer of infectious measles virus in trivalent, live, measles, mumps, rubella vaccines (MMR). Here we describe the further improvement and development of the assay for simultaneous potency estimation of measles, mumps and rubella viruses. The potency of measles and mumps virus is estimated within one assay after 1 day of cell culture. The potency of rubella virus is estimated in a separate assay after 2 days of cell culture. Compared to conventional CCID50 and plaque assays, the quantitative PCR infectivity assay has the advantage in being fast because the assay is not dependent on the formation of cytopathic effect. Furthermore assay design is simplified: serological neutralization can be omitted because PCR is virus-specific and, under the conditions used, the individual components of trivalent measles, mumps, rubella vaccines do not interfere with each other. The assay was validated and compared to the performance of a plaque assay.
Insights
A refined quantitative PCR infectivity assay rapidly estimates measles, mumps, and rubella virus potency in vaccines. This method offers a faster, simplified alternative to traditional assays for MMR vaccine quality control.
Area of Science:
- Virology
- Molecular Biology
- Vaccine Development
Background:
- The quantitative PCR infectivity assay combines virus propagation with quantitative PCR.
- Previous work estimated measles virus titers in measles, mumps, rubella (MMR) vaccines.
Purpose of the Study:
- To improve and develop the quantitative PCR infectivity assay for simultaneous potency estimation of measles, mumps, and rubella viruses.
- To streamline vaccine potency testing by reducing assay time and complexity.
Main Methods:
- Developed a quantitative PCR infectivity assay for simultaneous potency estimation of measles and mumps viruses within one day.
- Utilized a separate assay for rubella virus potency estimation after two days of cell culture.
- Validated the assay and compared its performance against a traditional plaque assay.
Main Results:
- The improved assay allows for rapid potency estimation of measles and mumps viruses in one day, and rubella virus in two days.
- The quantitative PCR infectivity assay is significantly faster than conventional cell culture infective dose 50 (CCID50) and plaque assays.
- Assay design is simplified by omitting serological neutralization due to PCR's virus specificity and lack of interference between vaccine components.
Conclusions:
- The enhanced quantitative PCR infectivity assay provides a rapid, simplified, and effective method for simultaneous potency estimation of measles, mumps, and rubella viruses in vaccines.
- This assay offers a significant advantage over conventional methods, particularly in terms of speed and reduced assay complexity.
- The assay was validated, demonstrating comparable performance to established plaque assays for MMR vaccine quality control.
